DEVELOPMENT OPTIMIZER™

DATA-DRIVEN SOLUTIONS FOR CLINICAL DEVELOPMENT

AN INNOVATIVE LOOK AT DRUG DEVELOPMENT

Development Optimizer empowers users to make data-driven drug development decisions by providing access to highly curated data plus analytic capabilities that are distinct in the clinical database marketplace. The result is a powerful business intelligence tool that can help biopharmaceutical R&D executives identify and mitigate risks, analyze key metrics of both success and failure in the drug creation process, prioritize projects and benchmark their own efforts against a relevant peer group of innovative companies.

Gain critical, actionable insight from:

- Attrition and advancement rates on a per project or compound basis and attrition causality
- Approval success rates for similar drugs in multiple therapeutic areas
- Mean clinical development and regulatory review times for approved drugs
- Termination efficienci for abandoned compounds
- Pipeline composition of competitors by therapeutic area, technology and molecular target

Development Optimizer is built on the complete clinical development histories of more than 242 biotechnology companies. The underlying compound and project records have been analyzed and indexed with over 200 search terms enabling a detailed view on how various factors affect clinical outcomes.

Attrition and Causality analyses take you beyond the percentages to the categorized reasons behind compound termination decisions. Compare attrition rates by therapeutic area, indication, technology, mechanism of action, partner, and license status to derive benchmark success rates for your own experimental agents.

Development and Regulatory Performance uses a proprietary matrix to plot clinical development times against regulatory review times and define "Leading Practice" for approved products, providing a new perspective on successful drugs.

Termination Efficiencyplots clinical development time against phase at termination and portrays "Leading Practice" for avoiding expensive, late-stage compound terminations. Learning from past failures and quantifying inefficien practice is central to improving future R&D performance.

ANALYTIC POWER FROM DEPTH OF DATA AND ORGANIZATION

- 2,300+ drug development records, updated every business day, each featuring a user-friendly, interactive clinical timeline that maps out key clinical development events.
- 6,600+ clinical trials - correlated with results for completed studies, including 5,300+ abstracts from medical meetings and peer reviewed journals plus links to clinicaltrials.gov and PubMed citations. All trial data is summarized using a proprietary, standardized taxonomy that allows direct comparisons of results.
- 1,100+ regulatory filin records that track special designation usage (e.g., Fast Track, Orphan Drug, and Accelerated Approval) and review cycle times with FDA and EMA briefin documents attached.
- Complete histories for compounds at all stages of development: Ongoing, Marketed, and Terminated. Records are supported by inspectable documents, including 17,500+ corporate press releases and other primary data sources.

THOMSON REUTERS™

DEVELOPMENT OPTIMIZER TOOLS

- The Pipeline Graph portrays active drug development pipelines by phase for all companies.
- The Company Clinical Summary page provides an overview of drug development statistics for each company, including charts showing Technology Focus and Therapeutic Area Focus. The Summary page provides a single, organized launch point for applying all of Development Optimizer's analytics to a single company.
- Development Optimizer provides the ability to print graphs and results, download a screenshot of the graph, or download the results list to Excel for additional analysis or executive presentations.
- The Compound/Project Development Record features Recap's proprietary interactive Clinical Timeline, which provides easy, one-stop access to a drug's development progress through time with alliances, clinical trials, press releases, regulatory documents, abstracts, and sponsor documents for each disease indication pursued with a given compound.
- Development Optimizer delivers complete transparency of the underlying data for all analyses, allowing users to drill down into the details.

ALSO IN THE IQ SERIES: TOOLS FOR ALLIANCE STRATEGIES AND VALUATIONS

Deal Builder™ and Valuation Analyzer™ are biopharma business intelligence tools for managing alliance formation, the lifecycle of the alliance, and deal valuations. Gain new insights into biopharma alliances with access to unredacted, unpublished agreements secured through Freedom of Information Act requests of the U.S. Securities and Exchange Commission.







Attrition and Causality
Utilizes a "waterfall" graph to show attrition rates (red bars) at each phase of development for all compounds that have reached a definitiv clinical outcome of success (licensure in at least one indication) or failure (termination in all indications) ongoing compounds are not counted.

Development and Regulatory Performance
Places drug development success stories within a relative "performance" matrix that portrays clinical development time along one axis and FDA regulatory review time along the other.

Termination Efficiency
Places drug development termination decisions within a matrix of clinical development time along one axis and phase at termination along the other.

Powerful Search Builder
Multiple filter search results and analyses by eight key parameters: Company, Therapeutic Area, Indication, Mechanism of Action, Technology, Partner Status, License Status, and FDA Regulatory Designations.

ABOUT RECAP

Recap from Thomson Reuters aims to provide analysis and advice for biopharmaceutical business development. Recap clients include biotechnology and pharmaceutical companies, universities, investment banking, and venture firms. More than 1,500 organizations utilize Recap's data services. Recap combines extensive deals analysis experience with the breadth of Life Sciences service offerings from Thomson Reuters creating a powerful combination for clients.

FOR MORE INFORMATION

Learn how Recap can help you do a good deal faster, visit **www.recap.com**

LS 201307

THOMSON REUTERS™